- Policy
- Akynzeo is licensed domestically
- by Kim, Jung-Ju Nov 3, 2022 05:54am
- The Ministry of Food and Drug Safety has landed in Korea with new drug imported by HK inno.N. The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) approved Akynzeo, an imported new drug of HKinno.N, on the 31st, which prevents nausea and vomiting caused by the administration of chemotherapy drugs. This is a drug for preventing acute a
- Policy
- NHI big data was used to evaluate safety of JAK inhibitors
- by Lee, Tak-Sun Nov 2, 2022 05:36am
- Big data from the National Health Insurance was found to have been used to evaluate the safety of JAK inhibitors, based on which its use has been restricted in high-risk patients in Korea. This is the first time that NHI big data had been used for safety evaluation of pharmaceuticals in Korea. The National Health Insurance Service’s Big
- Policy
- "Synthetic Biology" that Moderna used
- by Kang, Shin-Kook Nov 2, 2022 05:36am
- The Act on Research Promotion and Support for Synthetic Biology' proposed legislation in the first half of next year. Support measures will be prepared for Synthetic Biology, which is evaluated to double the efficiency of research and development of innovative new drugs and materials. Deputy Prime Minister for Economic Affairs and Minister of
- Company
- Hanmi achieves record quarterly performance in 7 years
- by Chon, Seung-Hyun Nov 2, 2022 05:36am
- Hanmi Pharmaceutical recorded the highest performance in 7 years since 2015. Its sales and operating profit were the largest since Q4 2015 when it signed a series of mega technology export deals, thanks to the success of its new combination drug and Beijing Hanmi. On the 1st, Hanmi Pharmaceutical officially announced that its operating profit
- Product
- A fierce battle between MDs & RPhs on Rx of ingredient names
- by Kang, Shin-Kook Nov 2, 2022 05:36am
- A fight between pharmaceutical organizations has begun over the prescription of ingredient names. Oh Yoo-kyung, head of the Ministry of Food and Drug Safety, made an excuse to actively agree to the prescription of the ingredient name, and complaints that have accumulated have been erupting. First, doctors are insisting that patients choose in-ho
- Company
- JW signs new anti-cancer drug R&D contract with KURE AI
- by Nho, Byung Chul Nov 2, 2022 05:35am
- JW Group announced on the 1st that it has signed a joint research contract with U.S. bio venture company KURE AI Therapeutics to develop innovative anti-cancer drugs based on artificial intelligence (AI). Under this contract, JW Pharma and JW CreaGene will launch research and development of three new anticancer drugs using KURE AI's artificia
- Company
- RET-targeted Retevmo reattempts reimb listing in Korea
- by Eo, Yun-Ho Nov 1, 2022 06:02am
- The RET-targeted anticancer therapy ‘Retevmo’ will reattempt reimbursement listing in Korea. According to industry sources, Lilly Korea’s Retevmo (selpercatinib) will be deliberated by the Health Insurance Review and Assessment Service’s Cancer Disease Review Committee (CDRC) tomorrow on November 2nd. Retevmo received marketing aut
- Policy
- LG Chemical completed Vimovo's domestic copyright
- by Lee, Tak-Sun Nov 1, 2022 06:02am
- LG Chem has acquired the domestic copyright of the complex "Vimovo," which combines NSAIDs-based anti-inflammatory analgesics (Naproxen) and PPI-based gastroesophageal reflux disease treatment ingredient Esomeprazole. Vimovo is a product released in Korea by AstraZeneca Korea in 2012 and has been jointly selling it with LG Chem. As Vimovo'
- Company
- Bukwang applies for approval of Lurasidone
- by Nov 1, 2022 06:02am
- Bukwang Pharmaceutical announced on the 31st that it has applied for an item permit for Lurasidone, a new drug for treating schizophrenia and bipolar depression, from the Ministry of Food and Drug Safety. Lurasidone is a treatment for depression with schizophrenia and bipolar disorder developed by Sumitomo Pharma, Japan. Bukwang Pharmaceutica
- Policy
- It doesn't mean that we're considering a reduction
- by Lee, Tak-Sun Nov 1, 2022 06:02am
- The Ministry of Health and Welfare explained in writing about Minister Cho Kyu-hong's answer to the government audit site on the 6th about Korea's generic insurance drug price, which was set at an expensive price. The remarks at the time came as Choi Jae-hyung, a lawmaker of the People's Power, responded to a question that "the price of gener
